Moreover, several studies showed that patients with diabetes and cardiovascular disease or at high cardiovascular risk who are treated with GLP-1 receptor agonists had a reduced risk of adverse cardiovascular events [57,58]. This evidence concerns the gene GLP1R and cardiovascular disorder.